Low-dose intranasal deferoxamine modulates memory, neuroinflammation, and the neuronal transcriptome in the streptozotocin rodent model of Alzheimer’s disease

IntroductionIntranasal (IN) deferoxamine (DFO) has emerged over the past decade as a promising therapeutic in preclinical experiments across neurodegenerative and neurovascular diseases. As an antioxidant iron chelator, its mechanisms are multimodal, involving the binding of brain iron and the conse...

Full description

Saved in:
Bibliographic Details
Main Authors: Jared M. Fine, Jacob Kosyakovsky, Tate T. Bowe, Katherine A. Faltesek, Benjamin M. Stroebel, Juan E. Abrahante, Michael R. Kelly, Elizabeth A. Thompson, Claire M. Westby, Kiley M. Robertson, William H. Frey, Leah R. Hanson
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-01-01
Series:Frontiers in Neuroscience
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fnins.2024.1528374/full
Tags: Add Tag
No Tags, Be the first to tag this record!